Open Access Articles- Top Results for B-cell lymphoma
Journal of Clinical Case ReportsPrimary Cutaneous Diffuse Large B-Cell Lymphoma with Tongue Involvement
Journal of Blood Disorders & TransfusionPrimary Cutaneous Diffuse Large B-Cell Lymphoma of the Leg: Apropos of a Fatal Case
Journal of Molecular and Genetic MedicinePredicting the survival time for diffuse large B-cell lymphoma using microarray data
Journal of Hematology & Thromboembolic DiseasesInteresting Collision between an Indolent B-Cell Lymphoma and a Microsatellite Unstable Adenocarcinoma of the Colon
Journal of Cancer Science & TherapyALK-postive Large B-cell Lymphoma: Report of Two Cases and Review of the Literature
|File:Large b cell lymphoma - cytology small.jpg|
|Classification and external resources|
|Specialty||Hematology and oncology|
|ICD-O||9680/0, 9699/3, 9699/3|
|Patient UK||B-cell lymphoma|
B-cell lymphomas include both Hodgkin's lymphomas and most non-Hodgkins lymphomas. They are typically divided into low and high grade, typically corresponding to indolent (slow-growing) lymphomas and aggressive lymphomas, respectively. As a generalisation, indolent lymphomas respond to treatment and are kept under control (in remission) with long-term survival of many years, but are not cured. Aggressive lymphomas usually require intensive treatments, with some having a good prospect for a permanent cure.
Prognosis and treatment depends on the specific type of lymphoma as well as the stage and grade. Treatment includes radiation and chemotherapy. Early-stage indolent B-cell lymphomas can often be treated with radiation alone, with long-term non-recurrence. Early-stage aggressive disease is treated with chemotherapy and often radiation, with a 70-90% cure rate. Late-stage indolent lymphomas are sometimes left untreated and monitored until they progress. Late-stage aggressive disease is treated with chemotherapy, with cure rates of over 70%.
There are numerous kinds of lymphomas involving B cells. The most commonly used classification system is the WHO classification, a convergence of more than one, older classification systems.
Five account for nearly three out of four patients with non-Hodgkin lymphoma:
- Diffuse large B cell lymphoma (DLBCL)
- Follicular lymphoma
- Marginal zone lymphoma (MZL) or Mucosa-Associated Lymphatic Tissue lymphoma (MALT)
- Small cell Lymphocytic lymphoma (overlaps with Chronic lymphocytic leukemia)
- Mantle cell lymphoma (MCL)
The remaining forms are much less common:
- Burkitt lymphoma
- Primary mediastinal (thymic) large B-cell lymphoma
- Lymphoplasmacytic lymphoma, which may manifest as Waldenström macroglobulinemia
- Nodal marginal zone B cell lymphoma (NMZL)
- Splenic marginal zone lymphoma (SMZL)
- Intravascular large B-cell lymphoma
- Primary effusion lymphoma
- Lymphomatoid granulomatosis
- T cell/histiocyte-rich large B-cell lymphoma
- Primary central nervous system lymphoma
- Primary cutaneous diffuse large B-cell lymphoma, leg type (Primary cutaneous DLBCL, leg type)
- EBV positive diffuse large B-cell lymphoma of the elderly
- Diffuse large B-cell lymphoma associated with inflammation
- Intravascular large B-cell lymphoma
- ALK-positive large B-cell lymphoma
- Plasmablastic lymphoma
- Large B-cell lymphoma arising in HHV8-associated multicentric Castleman disease
- B-cell lymphoma, unclassifiable with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma
- B-cell lymphoma, unclassifiable with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma
Additionally, some researchers separate out lymphomas that appear to result from other immune system disorders, such as AIDS-related lymphoma.
Associated chromosomal translocations
Chromosomal translocations involving the immunoglobulin heavy locus (IGH@) is a classic cytogenetic abnormality for many B-cell lymphomas, including follicular lymphoma, mantle cell lymphoma and Burkitt's lymphoma. In these cases, the immunoglobulin heavy locus forms a fusion protein with another protein that has pro-proliferative or anti-apoptotic abilities. The enhancer element of the immunoglobulin heavy locus, which normally functions to make B cells produce massive production of antibodies, now induces massive transcription of the fusion protein, resulting in excessive pro-proliferative or anti-apoptotic effects on the B cells containing the fusion protein.
In Burkitt's lymphoma and mantle cell lymphoma, the other protein in the fusion is c-myc (on chromosome 8) and cyclin D1 (on chromosome 11), respectively, which gives the fusion protein pro-proliferative ability. In follicular lymphoma, the fused protein is Bcl-2 (on chromosome 18), which gives the fusion protein anti-apoptotic abilities.
- Merck Manual home edition, Non-Hodgkin Lymphomas
- "The Lymphomas" (PDF). The Leukemia & Lymphoma Society. May 2006. p. 12. Retrieved 2008-04-07.
- Mazen Sanoufa, Mohammad Sami Walid, Talat Parveen (2010). "B-Cell Lymphoma of the Thoracic Spine Presenting with Spinal Cord Pressure Syndrome". JOCMR 2 (1): 53–54. doi:10.4021/jocmr2010.02.258w.
- "HMDS: Hodgkin's Lymphoma". Archived from the original on 4 March 2009. Retrieved 2009-02-01.
- Li JY, Gaillard F, Moreau A et al. (May 1999). "Detection of translocation t(11;14)(q13;q32) in mantle cell lymphoma by fluorescence in situ hybridization". Am. J. Pathol. 154 (5): 1449–52. PMC 1866594. PMID 10329598. doi:10.1016/S0002-9440(10)65399-0.
- Overview and video at harvard.edu
- Lymphoma Association – Specialist UK charity providing free information and support to patients, their families, friends and carers